Korsana Biosciences (KRSA) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 90.0% versus a gain of 0.8%. Over five years, PAHC leads with a +71.6% price change compared with -91.1% for KRSA. Korsana Biosciences is the larger company by market cap ($1.53 billion vs $1.52 billion), about 1.0 times the size, while Phibro Animal Health is growing revenue faster (+17.1% vs +3.7%).
Phibro Animal Health pays a dividend yielding 1.28%, while Korsana Biosciences does not currently pay one. Phibro Animal Health converts more of its revenue into profit, with a net margin of 6.6% versus -170.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | PAHC |
|---|---|---|
| Share price | $33.51 | $37.40 |
| Market cap | $1.53B | $1.52B |
| 1-day change | +6.37% | -0.85% |
| YTD return | +276.94% | +0.11% |
| 1-year return | +89.97% | +0.78% |
| 5-year return | -91.10% | +71.56% |
| P/E ratio (TTM) | — | 15.39 |
| Forward P/E | — | 9.73 |
| EPS (TTM) | $-7.07 | $2.43 |
| Dividend yield | 0.00% | 1.28% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $2.07M | $1.52B |
| Revenue growth (YoY) | +3.70% | +17.12% |
| Net income (latest FY) | $-3.53M | $99.72M |
| Gross margin | — | 33.76% |
| Operating margin | -239.78% | 12.81% |
| Net margin | -170.11% | 6.57% |
| 52-week high | $59.36 | $60.08 |
| 52-week low | $7.19 | $28.25 |
| Distance from 52-week high | -43.55% | -37.75% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +31.30% | +17.65% |
| Average volume | 32.06K | 236.19K |
| Shares outstanding | 45.54M | 21.11M |
| Employees | 19 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed PAHC by 89.2 percentage points over the past year.
- Phibro Animal Health offers a meaningfully higher dividend yield (1.28% vs 0.00%).
- Phibro Animal Health is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -170.1 cents for Korsana Biosciences.
- Phibro Animal Health grew revenue faster in its latest fiscal year (+17.12% vs +3.70%).
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
KRSA vs PAHC FAQ
Which is bigger, Korsana Biosciences or Phibro Animal Health?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.53B compared with $1.52B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, KRSA or PAHC?
KRSA returned +89.97% over the past 12 months, compared with +0.78% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Korsana Biosciences or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.28%, while Korsana Biosciences does not currently pay a regular dividend.
Are Korsana Biosciences and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.